CBIS Expands Licensing Deal with Purple Haze Properties as it Launches 'Jimi's Cannabis Collection' Today at the Chicago 'Marijuana Business Conference and Expo'
VISIT ANDREW PITSICALIS, CEO OF PURPLE HAZE PROPERTIES, TODAY IN CHICAGO, REPRESENTING INDIVIDUAL & JOINT MEDICINAL PRODUCTS CREATED WITH CBIS FOR 'JIMI'S CANNABIS COLLECTION' INCLUDING GENETIC STRAINS & PRODUCTS
COLORADO SPRINGS, Colo., May 19, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in cannabis formulation-based drug development and related consulting, today announced that Purple Haze Properties CEO Andrew Pitsicalis will be representing individual and joint medicinal products created with CBIS for "Jimi's Cannabis Collection" including genetic strains and products at the Chicago "Marijuana Business Conference and Expo." Cannabis Science and Purple Haze Properties are working together to launch exciting lines of quality cannabis products using scientific genetics and creating an education platform to share information from doctors and patients around the world about the advances of cannabis research.
Purple Haze Properties will be launching its concept of the Purple Haze Lounges worldwide and will be looking at Denver and Los Angeles for the first ground breaking locations and then Jamaica and Vancouver, B.C, as potential international future locations. These 20,000 sq. ft. "Ultra Lounges" will have a concert hall, restaurants, VIP memberships and charity foundation with themed social areas. We want to give the patron and performer an amazing cultural experience. The property will utilize the best music and video technologies and have some of the finest functional glass art ever seen.
Making its debut is the launch of Jimi's Cannabis Collection, a lifestyle brand dedicated to the greatest guitarist in rock and roll history. We decided to launch our brand at the "Marijuana Business Conference and Expo" today in Chicago, "America's oldest and largest national cannabis trade show." Purple Haze Properties is launching Jimi's Cannabis Collection of strains, edibles, and medical CBD topical creams, lotions and throat spray. The medical line will aid in relieving symptoms, such as pain management for throat issues, scars, burns and skin cancer. Jimi's three divisions will cover major areas of the cannabis industry. "Jimi's Genetix" is the division for strains and concentrates. "Jimi's Edibles" is the division of consumable products and "Jimi's Meds" is for non-psychoactive, CBD & Cannabinoid, pharmacy grade, topical throat, and pain management solutions.
Cannabis Science will help Purple Haze educate people by having kiosks in the facilities to educate self-medicating patients, to inform about historical cannabis diagnosed ailments and conditions. The high tech kiosk displays will provide educational access to consumers in regards to historical prescriptions, historical and relative strain and dosage for ailments. It will also provide the public with historical and scientific information about cannabinoids and other elements contained in the plant. This up to date information provided by CBIS will inform the patron about advances in research that are allowing cannabis to battle crippling diseases we face today.
As Cannabis Science does not support smoking as a delivery mechanism or advocate for recreational use, CBIS will help Purple Haze Properties in the creation of pharmaceutical grade CBD products for Jimi's Cannabis Collection. The goal is to help those patients find a natural alternative to pharmaceutical drugs prescribed today. Jimi's Cannabis Collection will be giving a portion of its proceeds from sales of its products to help in scientific research to help find effective treatments for AIDS, various cancers, PTSD, and other health traumas. These donations from Jimi's Cannabis Collection will go to CBIS, Cannabis Science, Inc. CBIS takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.
Purple Haze Properties CEO and President Andrew Pitsicalis stated, "We are very pleased to be working with Cannabis Science and licensing our brand to additional companies worldwide. We will license to those who have the legal rights to produce, cultivate and dispense cannabis in medical or recreational states nationwide. We also have plans to expand to over 25 countries, which have legalized or decriminalized Cannabis."
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.